Calliditas Therapeutics to Present Nefecon Data at the 17[th] International Symposium on IgA Nephropathy (IIgANN) September 25-27 in Tokyo September 19, 2023 16:00 CET Non Regulatory Read more
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy August 18, 2023 10:00 CET Regulatory Read more
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet August 15, 2023 08:00 CET Non Regulatory Read more
Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib July 13, 2023 08:00 CET Non Regulatory Read more
Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO[®] June 21, 2023 09:00 CET Non Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 30, 2023 16:00 CET Regulatory Read more
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 May 5, 2023 14:30 CET Non Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 28, 2023 08:30 CET Regulatory Read more
Calliditas to participate in upcoming investor conferences March 31, 2023 17:00 CET Non Regulatory Read more
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy February 2, 2023 09:15 CET Non Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
